Aquestive therapeutics to present anaphylm™ (epinephrine) sublingual film pharmacokinetic and pharmacodynamic data at the 2024 aaaai annual meeting

Warren, n.j., feb. 15, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (the “company” or “aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the positive pharmacokinetic (pk) and pharmacodynamic (pd) data from two completed clinical studies for anaphylm will be presented at the american academy of allergy, asthma, and immunology (aaaai) 2024 annual meeting, which will take place february 23-26 in washington, d.c. as highlighted in the abstract, anaphylm pk and pd data were comparable to epinephrine delivered via autoinjector or manual intramuscular injection (im).
AQST Ratings Summary
AQST Quant Ranking